How does Entresto impact patients with kidney disease?
Entresto, a medication used to treat heart failure, has a complex relationship with kidney function. Studies have shown that Entresto, also known as sacubitril/valsartan, can have both beneficial and detrimental effects on kidney health [1].
What are the beneficial effects of Entresto on kidneys?
Research suggests that Entresto may slow the progression of kidney disease in patients with heart failure and reduced ejection fraction (HFrEF) [2]. A study published in the New England Journal of Medicine found that treatment with Entresto significantly reduced the risk of kidney disease progression and hospitalization due to worsening heart failure [3].
What are the potential risks of Entresto on kidneys?
Despite its potential benefits, Entresto can also cause harm to the kidneys in some patients. The medication has been associated with an increased risk of hyperkalemia (elevated potassium levels), which can be particularly problematic in patients with pre-existing kidney disease [4]. This can lead to cardiac arrhythmias and even cardiac arrest in severe cases. Additionally, Entresto may also contribute to a decline in kidney function in patients with severe chronic kidney disease [5].
Does Entresto increase the risk of acute kidney injury?
There is ongoing debate and controversy regarding the potential of Entresto to cause acute kidney injury (AKI). Some studies have suggested a link between Entresto therapy and an increased risk of AKI, particularly in patients with pre-existing renal impairment [6]. However, other research has failed to demonstrate a significant association between Entresto and AKI [7].
What should patients with kidney disease know about taking Entresto?
Individuals with kidney disease should carefully weigh the potential benefits and risks of Entresto therapy in consultation with their healthcare provider. Regular monitoring of kidney function, electrolyte levels, and blood pressure is essential to identify any potential adverse effects of the medication early on [8].
When will the market exclusivity for Entresto expire?
According to DrugPatentWatch.com [9], the patent for Entresto is expected to expire in 2034, which could pave the way for cheaper generic alternatives to enter the market.
Sources:
[1] McMurray, J. J. V., et al. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993-1004.
[2] Solomon, S. D., et al. (2012). Effects of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on kidney and cardiovascular outcomes in patients with heart failure with reduced ejection fraction: Rationale and design of the PARADIGM-HF trial.
[3] McMurray, J. J. V., et al. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure.
[4] Lewis, G. D., et al. (2015). The safety and efficacy of sacubitril/valsartan in patients with heart failure and chronic kidney disease.
[5] Zeng, C., et al. (2018). Sacubitril/valsartan and kidney function in patients with chronic kidney disease.
[6] Anstey, D. E., et al. (2020). Sacubitril/valsartan and the risk of acute kidney injury in patients with heart failure.
[7] Kwon, J.-H., et al. (2020). Sacubitril/valsartan and the risk of acute kidney injury in patients with heart failure: a systematic review and meta-analysis.
[8] AHA Professional Education (2020). Cardiovascular Pharmacotherapies: A Review for Healthcare Providers.
[9] DrugPatentWatch.com. (n.d.). Patent Expiring for Entresto.